

Format for Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part A: Details of Acquisition

1.	Name of the Target Company (TC)	BALAXI PHARMACEUTICALS LIMITED (formerly known as Balaxi Ventures Limited)		
2.	Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	EBISU Global Opportunities Fund Limited		
3.	Whether the acquirer belongs to Promoter / Promoter group	No		
4.	Name(s) of the Stock Exchange(s) where the shares of TC are Listed	National Stock Exchange of India Limited (NSE)		
5.	Details of the acquisition/ disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
6.	Before the acquisition/sale under consideration, holding of:			
	a) Shares carrying voting rights	4,521,028	8.19%	NIL
	b) Shares in the Nature of encumbrance (pledge / lien /non-disposal undertaking / others)	NIL	NIL	NIL
	c) Voting rights (VR) otherwise than by equity shares	NIL	NIL	NIL
	d) Warrants/convertible securities/ any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	NIL	NIL	NIL
	e) Total (a+b+c+d)	4,521,028	8.19%	NIL
7.	Details of acquisition/sale			
	a) Shares carrying voting rights acquired/ sold	1,345,891	2.44%	NIL
	b) VRs acquired otherwise than by equity shares	NIL	NIL	NIL
	c) Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired.	NIL	NIL	NIL
	d) Shares in the Nature of encumbrance (pledge/ lien/non-disposal undertaking/ others)	NIL	NIL	NIL
	e) Total (a+b+c+d)	1,345,891	8.19%	NIL
8.	After the acquisition/sale, holding of:			
	a) Shares carrying voting rights	3,175,137	5.75%	NIL
	b) Shares in the Nature of encumbrance (pledge / lien / non-disposal	NIL	NIL	NIL

	undertaking / others) Shares pledged with the acquirer.			
	c) VRs otherwise than by equity shares	NIL	NIL	NIL
	d) Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	NIL	NIL	NIL
	e) Total (a+b+c+d)	3,175,137	5.75%	NIL
9.	Mode of acquisition/ sale (e.g. open market / off Market/ public issue / rights issue /preferential allotment / inter-se transfer, etc.)	Sale in Open Market		
10.	Date of acquisition of / date of receipt of intimation of allotment of shares / VR / warrants / convertible securities / any other instrument that entitles the acquirer to receive shares in the target company	Sale of 2,386 shares on March 19, 2025; Sale of 100,000 shares on March 26, 2025; Sale of 150,000 shares on March 27, 2025; Sale of 125,000 shares on March 28, 2025; Sale of 250,000 shares on April 02, 2025; Sale of 59 shares on April 03, 2025; Sale of 298,446 shares on April 04, 2025; Sale of 150,000 shares on April 09, 2025; Sale of 270,000 shares on April 24, 2025;		
11.	Equity share capital / total voting capital of the TC before the said acquisition/ sale	55,207,500 (Five Crores Fifty-Two Lakhs Seven Thousand, Five Hundred) equity shares having face value of Rs. 2 (Rupees Two only) each.		
12.	Equity share capital/ total voting capital of the TC after the said acquisition/ sale	55,207,500 (Five Crores Fifty-Two Lakhs Seven Thousand, Five Hundred) equity shares having face value of Rs. 2 (Rupees Two only) each.		
13.	Total diluted share/voting capital of the TC after the said acquisition/ sale	55,207,500 (Five Crores Fifty-Two Lakhs Seven Thousand, Five Hundred) equity shares having face value of Rs. 2 (Rupees Two only) each.		

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

for EBISU Global Opportunities Fund Limited



Nitin Singhal
Director

Date: April 28, 2025

Place: UAE

Part B

Name of Target Company: BALAXI PHARMACEUTICALS LIMITED (formerly known as Balaxi Ventures Limited)

Names of Acquirer and Persons acting in Concert (PAC) with the Acquirer	Whether the Acquirer belongs to the Promoter / Promoter Group	PAN of the Acquirer and / or PAC
EBISU Global Opportunities Fund Limited	No	

for EBISU Global Opportunities Fund Limited



Nitin Singhal
Director

Date: April 28, 2025

Place: UAE